|
|
 |
|
Viewing report
|
|
|
|
Chemical Genomics - Commercial Applications in Drug Discovery and Development
Drug and Market Development Publishing, July 2004
The time, cost, and complexity of the process of drug discovery can be drastically reduced through the application of chemical genomics and chemogenomics. The understanding and identification of the roles of chemistry and biology early in the development process will lessen not only the time of pre-clinical development, but also the risk of late clinical development failure. To achieve this acceleration of the processes, chemical genomics/chemogenomis integrates the latest developments in tools and technologies from a variety of disciplines; including combinatorial chemistry, informatics, synthetic chemistry, cell-based assays, microarrays, genomics, bioinformatics, toxicogenomics, and proteomics.
Key Reasons to Buy
1. Get a clear definition of chemical genomics and chemogenomics via an in-depth review of their current usage and applications adopted by several companies.
2. Understand the current intellectual property landscape from a detailed summary of chemical genomics/chemogenomics patents.
3. Gain reliable and thought-provoking insights into the chemical genomics/chemogenomics forecast through interviews with industry experts.
4. Look inside companies working within the chemical genomics and chemogenomics markets, including their product pipelines, partnerships & alliances, business strategies, technologies, and more.
Report Scope
The Chemical Genomics Report provides an in-depth analysis of the promising market for chemical genomics and chemogenomics. The Report thoroughly examines chemical genomics and chemogenomics, their potential applications in the development of therapeutics for human diseases, and recent technology advancements. In addition, the intellectual property landscape is summarized, companies invested in chemical genomics and chemogenomics are profiled, and key industry players are interviewed
Market Opportunities
- Utilize chemical genomics/chemogenomics to significantly reduce the time and cost of the drug discovery cycle.
- Employ chemical genomics/chemogenomics early in the drug development process in order to reduce the time, cost, and attrition associated with it.
- Integrate multiple discovery tools and technologies for chemical genomics in order to lessen the risks, costs, and time coupled with drug discovery and development.
Company Profiles
Acadia Pharmaceuticals
Amphora Discovery Corp
Astex
ChemGenex Therapeutics
ComGenex International
Graffinity Pharmaceuticals
Iconix Pharmaceuticals
Infinity Pharmaceuticals
Morphochem
NeoGenesis
Vertex Pharmaceuticals
Customers who bought this item also bought
Genomics in Drug Discovery and Development
Genomics World Markets 2008
Transforming Drug Discovery through Genomics and Proteomics
Drug Targets from Genomics: Evolving Tools for Discovery
Chemical Genetics in Drug Discovery
Genomics Players: From Discovery to Integration- Business and Technology Assessment, 2002
Drug Discovery--European Advances in Genomics and Proteomics (Technical Insights)
Aminoglycoside Antibiotics: From Chemical Biology to Drug Discovery
Drug Discovery and Development, Volume 2, Drug Development
Proteases as Drug Targets: Technologies and Opportunities for Drug Discovery
Organic and Medicinal Chemistry in Drug Discovery: Pharma's Intelligent Design
The Global Functional Genomics Industry
|
|
|
|
